Regeneron, playing catch up with J&J and Pfizer, wins FDA approval for Lynozyfic in multiple myeloma

Regeneron's linvoseltamab (Lynozyfic) has received FDA approval for heavily pretreated multiple myeloma patients (≥4 prior lines), positioning it as a new competitor against existing BCMA-targeted therapies like J&J's Tecvayli and Pfizer's Elrexfio. Lynozyfic demonstrated competitive efficacy, including a 70% overall response rate and 45% complete response rate in its pivotal trial, alongside a potentially more favorable cytokine release syndrome profile and a less frequent monthly dosing option for responders. This approval, following prior manufacturing delays, enhances Regeneron's oncology portfolio, with ongoing Phase 3 trials and potential future expansion into autoimmune indications.

Analysis

Regeneron has secured a significant FDA approval for Lynozyfic (linvoseltamab) in heavily pretreated multiple myeloma, positioning it as a potent competitor in the BCMA-targeted therapy class against Johnson & Johnson's Tecvayli and Pfizer's Elrexfio. The drug's clinical profile appears highly competitive, demonstrating a 70% overall response rate and a 45% complete response rate, which surpasses the label data for both Tecvayli (68% ORR, 31% CR) and Elrexfio (56% ORR, 25% CR). Key differentiating factors include a more favorable safety profile, with a notably lower rate of cytokine release syndrome (CRS) at 46% versus 72% for Tecvayli and 58% for Elrexfio, and a more convenient once-monthly dosing schedule for responders. Although the approval was delayed by manufacturing issues and is currently an accelerated one, the fully enrolled Phase 3 Linker-MM3 trial provides a clear path to potential full approval. Furthermore, management's commentary signals strategic intent to expand linvoseltamab's application into autoimmune diseases and advance another bispecific, odronextamab, reinforcing the strength and growth potential of Regeneron's oncology pipeline.

Key Decisions for Investors

• Given Lynozyfic's superior efficacy and safety profile compared to established competitors, investors should view this approval as a material positive for Regeneron's revenue outlook in a competitive oncology segment.
• Holders of Johnson & Johnson and Pfizer should monitor for potential market share erosion for Tecvayli and Elrexfio, as Lynozyfic's data may drive preferential adoption by clinicians.
• Key upcoming catalysts for Regeneron include the results from the confirmatory Linker-MM3 trial and any formal announcements regarding the expansion of linvoseltamab into autoimmune indications, which could significantly increase the drug's total addressable market.
• Investors should note that the approval is for a late-line setting (≥4 prior therapies), and while the infection rate (38% grade 3/4) is a risk factor, the drug's overall competitive standing appears strong pending further real-world data.